Meeting
2017 ASCO Annual Meeting
Assessment of established patient reported outcomes (PROs) instruments measuring toxicities and quality of life (QOL) for patients (pts) with head and neck cancer (HNC) treated on ECOG 1308 and 2399 studies.
Authors
Anthony Cmelak
Vanderbilt University Ingram Cancer Center, Nashville, TN
Anthony Cmelak , Yael Flamand , Shuli Li , Shanthi Marur , Barbara A. Murphy , David Cella , Arlene A. Forastiere , Barbara Burtness
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Head and Neck Cancer
Track
Head and Neck Cancer
Sub Track
Local-Regional Disease
Clinical Trial Registration Number
NCT01084083
Citation
J Clin Oncol 35, 2017 (suppl; abstr 6074)
DOI
10.1200/JCO.2017.35.15_suppl.6074
Abstract #
6074
Poster Bd #
62
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Quality Care Symposium
Patient-reported outcomes and financial toxicity in head and neck cancer (PaRTNer): Longitudinal assessment of financial toxicity and associated quality of life from a pilot study.
First Author: Pooja Karukonda
Poster
2018 ASCO-SITC Clinical Immuno-Oncology Symposium
Checkpoint inhibitors assessment in oropharynx carcinoma (CIAO).
First Author: Renata Ferrarotto
Poster
2016 Palliative and Supportive Care in Oncology Symposium
Patient reported outcomes (PROs) in patients with human papilloma virus (HPV) positive versus negative head and neck cancer (HNC).
First Author: Jessica Ruth Bauman
Poster
2015 ASCO Annual Meeting
Symptom reduction from IMRT dose deintensification: Results from ECOG 1308 using the Vanderbilt Head and Neck Symptom Survey version 2 (VHNSS V2).
First Author: Anthony Cmelak